This website uses cookies to enhance the user experience.
C

CURIDA HOLDING AS915 299 679

Process industry
Limited company
Solbærvegen 5 2409 ELVERUM, Norge

CURIDA HOLDING AS

Keywords

productionpharmaceuticalsantiserablood fractionsvaccineshomeopathic preparationscontraceptive productsbone buildingdiagnostic preparationspregnancy testsbiotechnological medicinescotton woolgasbandagesdressings

Organization

Chairman of the board
Years since formation
9 years
since Apr 25, 2015
Type
Limited company
VAT registered
Yes
Number of employees
0

Ownership

Number of shares and share classes
3,510,560
1 share class
Total number of shareholders
7
companies
Belongs to group of

Financials

Annual total result 2023
-66,747,932
NOK
Total equity 2023
6,681,228
NOK
Last update: Aug 29, 2024

Management

Management / administration

NameRoleShares
Managing Director/CEO-

Board

NameRoleShares
Chairman-
Board Member-
Board Member-
Board Member-
Board Member-
Board Member-
Alternate Member-
Alternate Member-

Others

NameRoleShares
K
KPMG AS
Auditor-
Accountant-

Top 10 individual shareholders

NameRoleShares
-
11.51 %
indirectly
-
11.51 %
indirectly
-
2.84 %
indirectly
-
2.84 %
indirectly
-
2.29 %
indirectly
Last update: Aug 3, 2024

Ownership

Company shareholders

NameShare classNumber of sharesShare
C
CANICA AS
NO0010822711
1,263,824
36 %
I
INVESTINOR DIREKTE AS
NO0010822711
1,016,612
28.96 %
K
KLAVENESS MARINE FINANCE AS
NO0010822711
808,436
23.03 %
P
PEDRO CONSULTING AS
NO0010822711
199,281
5.68 %
S
STOKKE INDUSTRI AS
NO0010822711
136,547
3.89 %
F
FLERBRUKSANLEGGET AS
NO0010822711
61,241
1.74 %
NO0010822711
24,619
0.7 %

Shares owned by the CURIDA HOLDING AS

NameShare classNumber of sharesShare
C
CURIDA AS
Ordinary shares
15,000
100 %
Å
ÅS PRODUKSJONSLAB AS
Ordinary shares
300
100 %
C
CURIDA DIATEC AS
Ordinary shares
1,446,981
99.98 %
Last update: May 24, 2024

Group structure

  • Total operating income 2023: NOK 0
    Operating profit 2023: NOK -2,541,435
    Employees: 0

Financials

in NOK

Summary

Year202320222021
Total operating income
0
0
0
Annual Total Result
-66,747,932
-177,764,505
4,080,532
Total assets
204,857,911
141,398,325
253,204,061
Total liabilities
198,176,683
141,354,442
75,395,675
Total equity
6,681,228
43,881
177,808,387

P&L

Year202320222021
Total operating income
0
0
0
Total operating costs
2,541,435
15,634,161
930,766
Operating result
-2,541,435
-15,634,161
-930,766
Financial income/costs
-64,206,497
-162,130,344
6,162,217
Profit before tax
-66,747,932
-177,764,505
5,231,451
Total tax & extraordinary income/cost
0
0
1,150,919
Annual Total Result
-66,747,932
-177,764,505
4,080,532

Balance overview

Year202320222021
Total fixed assets
92,792,251
32,424,002
176,453,653
Total current assets
112,065,661
108,974,323
76,750,408
Total assets
204,857,911
141,398,325
253,204,061
Short term debt
94,045,040
48,460,534
15,070,942
Long term debt
104,131,643
92,893,908
60,324,733
Total liabilities
198,176,683
141,354,442
75,395,675
Contributed capital
3,510,560
51,835,613
165,550,861
Retained earnings
3,170,669
-51,791,732
12,257,526
Total equity
6,681,228
43,881
177,808,387
Total equity and liabilities
204,857,911
141,398,323
253,204,062

Classification

Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
C
Main industrial area
Manufacturing
21
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.2
Main industrial group
Manufacture of pharmaceutical preparations
21.20
Industrial group
Manufacture of pharmaceutical preparations
21.200
Industrial group
Manufacture of pharmaceutical preparations